Authors
Aditya Shreenivas, Sewanti Limaye, Massimo Cristofanilli, Matt Lechner, Andrew M Gaya, Tim Crook, Pollyanna Leite, Kefah Mokbel, Dorthe Schaffrin-Nabe, Humaid O Al-Shamsi, Darshana Patil, Rajan Datar, Razelle Kurzrock
Published in
iScience. Volume 29. Issue 11. Pages 117893. Nov 20, 2026. Epub Oct 14, 2026.
Abstract
Liquid biopsy using circulating tumor DNA (ctDNA) is increasingly used for cancer profiling and monitoring, but blood-based analysis may not capture tumor heterogeneity across anatomical compartments. We evaluated cell-free DNA from cerebrospinal (n = 7), pleural (n = 11), pericardial (n = 1), and ascitic (n = 26) fluids from 45 patients with advanced cancer, comparing molecular findings with matched tissue, blood, and cytology where available. Oncogenic alterations were detected in 87% of body fluid samples, with a median variant allele frequency of 3.15%. TP53 (49%), EGFR (18%), and KRAS (18%) were the most frequently altered genes, and ESCAT tier IA alterations occurred in 31.1% of patients. In six patients (13.3%), potentially targetable alterations were detected in body fluids but not in blood and/or tissue. Among five cytology-negative samples, four were ctDNA positive. These findings support body fluid ctDNA profiling as a complementary approach to tissue, plasma, and cytology, thereby warranting prospective validation.
PMID:
42926854
Bibliographic data and abstract were imported from PubMed on 25 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 28
- Comments 0